Fragrance Creators Association: Risk-Based Assessments For Ingredients Aren't Broken

With cosmetics industry readying to confront wave of hazard-based regulations in Europe, Fragrance Creators Association publishes white paper to shore up advocacy efforts supporting risk-based assessments.

• Source: Shutterstock

Identifying potentially problematic fragrance ingredients using hazard-based criteria, the Fragrance Creators Association cautions, is a “blunt-force approach” which inadequately measures actual ingredient risk or the likelihood of harm and could lead to a problematic regulatory environment.

More from ESG

AESGP Slams ‘Deeply Concerning And Discriminatory’ EU Wastewater Directive

 
• By 

“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.

‘We All Have To Start Somewhere’: How Retailers Are Shaping Perrigo’s Climate Ambitions

 
• By 

Perrigo's retail customers are expecting real "net zero" progress from consumer health manufacturers, which is in turn driving the firm's sustainability ambitions and expectations from their own suppliers, Perrigo’s UK ethical compliance lead Isobel Gay tells HBW Insight in this exclusive interview.

EU Urban Wastewater Directive ‘Highly Disproportionate,’ Says AESGP

 
• By 

Pharmaceutical industry associations are united in their view that the revised EU Urban Wastewater Treatment Directive discriminates against medicines and cosmetics producers.

Kenvue’s Carlton Lawson: Reverse-Switching Antimicrobials ‘Not The Answer’ To AMR

 
• By 

Kenvue's EMEA and LATAM head Carlton Lawson acknowledges the urgency of environmental issues like antimicrobial resistance and wastewater pollution in this interview with HBW Insight, but calls for a more balanced approach on the part of European regulators.

More from HBW Insight

Reducing Complexity Helps Weleda Break Sales Record

 
• By 

Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.

Pharma Exhales, Dodges Financial Blow With Tariff Exemption

 

Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.

US FDA Restructuring May Be Next After Drugs Center Loses More Than 1,000 People

 

The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.